Clinical Evidence: Wegovy vs Mounjaro Safety Comparison
Understanding Wegovy Side Effects Hair Loss vs Mounjaro Hair Loss Reports
When comparing Wegovy side effects hair loss with Mounjaro, both medications showed minimal hair loss reports in their respective clinical trials. Wegovy (semaglutide) acts as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors, potentially creating different side effect profiles. In the STEP trials for Wegovy, hair loss was not identified as a common adverse event, occurring in less than 1% of participants. Similarly, Mounjaro's SURMOUNT trials reported minimal hair loss incidents, suggesting both treatments have comparable low risks for this particular concern.
The mechanism behind potential hair loss with either medication may relate to rapid weight changes rather than direct drug effects. Both Wegovy and Mounjaro can support significant weight management when used alongside reduced-calorie diet and increased physical activity. Any hair thinning typically resolves as the body adjusts to the new weight, making this a temporary rather than permanent concern for most patients considering either treatment option.
Pricing Comparison: Wegovy vs Mounjaro Treatment Costs
EverydayMeds offers competitive pricing for both Wegovy and Mounjaro, allowing you to choose based on clinical suitability rather than cost constraints. Wegovy pricing starts at £79.99 for the 0.25mg starter dose with discount code FIRST40 for new customers, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Returning customers can use code DOSE25 at checkout for continued savings across all dose strengths.
Our bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg & 1mg) for £299.99, supporting your first three months of treatment. The Ultimate Stability Trio offers three months of 2.4mg maintenance doses for £649.99, ensuring consistent supply without repeated ordering. Both Wegovy and Mounjaro require similar dose escalation protocols, though Mounjaro offers six dose levels (2.5mg to 15mg) compared to Wegovy's five standard doses (0.25mg to 2.4mg).
Clinical Evidence: STEP vs SURMOUNT Trial Safety Data
The STEP trials demonstrated Wegovy's safety profile across multiple studies, with hair loss not featuring among common side effects reported by Wilding et al., NEJM, 2021. Most participants experienced gastrointestinal effects during initial weeks, which typically resolved as treatment continued. The STEP programme involved over 4,500 participants across different populations, providing robust safety data for regulatory approval.
Mounjaro's SURMOUNT trials similarly showed minimal hair loss reports, with the dual GIP/GLP-1 mechanism potentially offering different tolerability patterns. Both medications carry MHRA additional monitoring status (Black Triangle ▼), ensuring continued safety surveillance post-approval. This comprehensive monitoring helps identify any rare side effects, including potential Wegovy side effects hair loss patterns that weren't apparent during initial clinical development.
How Wegovy Works: GLP-1 Mechanism vs Mounjaro's Dual Action
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. This mechanism works directly on brain appetite centres, potentially reducing food cravings whilst supporting sustainable eating pattern changes. The once-weekly injection maintains steady hormone levels, providing consistent appetite management throughout your treatment journey. Wegovy's single-target approach has extensive clinical validation, with the 2.4mg maintenance dose showing optimal efficacy in weight management trials. Any potential Wegovy side effects hair loss would likely result from the weight management process rather than direct hormonal interference with hair growth cycles.
EverydayMeds Ordering Process: Clinical Assessment to Delivery
Starting your Wegovy or Mounjaro treatment begins with our comprehensive 3-minute online clinical assessment, evaluating your medical history, current medications, and weight management goals. Our qualified prescribers review each application within 3 working days (express 24-hour service available), ensuring appropriate treatment selection based on individual circumstances. Following approval, your prescription-only medicine ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our ongoing clinical support includes dose escalation guidance and monitoring for any side effects, including potential Wegovy side effects hair loss concerns. The GPhC-registered pharmacy team (#9012878) remains available throughout your treatment journey for questions or adjustments needed.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
Both medications require refrigerated storage at 2-8°C before first use, but Wegovy offers superior travel convenience with 6 weeks room temperature stability versus Mounjaro's 21-day limit. The FlexTouch pen design ensures accurate dosing with minimal injection discomfort, whilst the dose escalation protocol helps minimise side effects during treatment initiation. Wegovy's established five-dose progression (0.25mg to 2.4mg) provides clear treatment milestones, compared to Mounjaro's six-dose range requiring more frequent adjustments. Most patients find the weekly injection routine manageable, with side effects including potential hair loss typically resolving within the first few months. Both treatments require commitment to dietary changes and increased physical activity for optimal results.
Hair Loss Concerns: Why Weight Management Medications May Affect Hair
Understanding Wegovy side effects hair loss requires recognising that rapid weight changes, regardless of method, can temporarily affect hair growth cycles. Both Wegovy and Mounjaro support significant weight management, which may trigger telogen effluvium—a temporary hair thinning condition related to physiological stress from weight changes rather than direct medication effects. This type of hair loss typically begins 2-3 months after starting treatment and resolves once weight stabilises at the maintenance phase.
The nutritional changes accompanying weight management can also influence hair health, making adequate protein and vitamin intake essential during treatment. Neither Wegovy nor Mounjaro directly interferes with hormonal pathways responsible for permanent hair loss patterns, suggesting any hair thinning experienced is likely temporary and reversible. Patients concerned about hair loss should discuss this with their prescriber, who can provide personalised guidance on supporting hair health throughout their weight management journey.
Making Your Choice: Expert Prescriber Guidance Available
Choosing between Wegovy and Mounjaro involves considering individual tolerance, medical history, and treatment preferences rather than simply comparing potential side effects like hair loss. Both treatments are available through EverydayMeds with comprehensive prescriber support to guide your decision-making process. Our clinical team evaluates factors including existing medications, previous weight management attempts, and specific health goals to recommend the most suitable option for your circumstances. Starting from £79.99 with discount codes FIRST40 (new customers) or DOSE25 (returning customers), either treatment represents a significant investment in your long-term health and wellbeing. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and receive expert guidance on whether Wegovy or Mounjaro aligns best with your individual needs and concerns about potential side effects.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
